The Technical Analyst
Medicure Inc. [MCUJF]
Exchange: PNK Industry: Biotechnology
Medicure Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.740
America/New_York / 26 apr 2024 @ 12:27
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.72 mill |
| EPS: | -0.0700 |
| P/E: | -10.57 |
| Earnings Date: | May 24, 2024 |
| SharesOutstanding: | 10.44 mill |
| Avg Daily Volume: | 0.0013 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -10.57 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -10.57 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.724 - 0.756 ( +/- 2.16%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.740 (0.00% ) |
| Volume | 0.0030 mill |
| Avg. Vol. | 0.0013 mill |
| % of Avg. Vol | 223.88 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MCUJF
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MCUJF
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Latest Press Releases
2024-04-23 17:00:00 - Press Release
Medicure Receives Us Fda Fast Track Designation For Mc-1 For Pnpo Deficiency
Winnipeg, mb / accesswire / april 23, 2024 / medicure inc. ("medicure" or the "company") (tsxv:mph)(otc pink:mcujf), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the united states market, announced today that through its subsidiary, medicure international inc., the u.s. food and drug administration (fda) has granted fast track designation for mc-1, an investigational product for the prevention or treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (pnpo) deficiency. fast track designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.
2024-04-08 17:00:00 - Press Release
Medicure Reports Financial Results For Quarter And Year Ended December 31, 2023
Winnipeg, mb / accesswire / april 8, 2024 / medicure inc. ("medicure" or the "company") (tsxv:mph)(otcpink:mcujf), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the united states market, today reported its results from operations for the quarter and year ended december 31, 2023. quarter and year ended december 31, 2023 highlights: recorded total net revenue of $21.7 million during the year ended december 31, 2023 compared to $23.1 million for the year ended december 31, 2022 and; recorded total net revenue of $5.1 million during the quarter ended december 31, 2023 compared to $6.3 million for the quarter ended december 31, 2022 and; recorded total net revenue from the sale of aggrastat® of $9...
2024-04-04 18:00:00 - Press Release
Medicure To Present Financial Results On April 9, 2024 Call At 8:30 Am Et For Quarter And Year Ended December 31, 2023
Winnipeg, mb / accesswire / april 4, 2024 / medicure inc. ("medicure" or the "company") (tsxv:mph)(otc pink:mcujf), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the united states market, will present the 2023 year end financial results on a conference call on april 9, 2024 at 8:30 am eastern time. the 2023 year end financials will be filed after closing april 8, 2024.
2023-12-05 17:00:00 - Press Release
Medicure Announces New Partnership Through Its Marley Drug Subsidiary To Provide Brenzavvy(r) As An Affordable Medication For Americans With Type 2 Diabetes
Winnipeg, mb / accesswire / december 5, 2023 / medicure inc. ("medicure" or the "company") (tsxv:mph)(otc pink:mcujf), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the united states market, through its pharmacy subsidiary marley drug®, a trusted national pharmacy known for its commitment to affordable healthcare solutions, is pleased to announce a partnership with theracosbio to distribute a newly approved diabetes drug, brenzavvy® (bexagliflozin) tablets, a sodium-glucose cotransporter-2 (sglt-2) inhibitor, at an affordable cash price delivered directly to patient homes in all 50 us states and territories...
2023-11-23 17:00:00 - Press Release
Medicure Announces Fda Provides Complete Approval To Enroll Patients In Its Pivotal Phase 3 Trial For Treatment Of Rare Pediatric Disease
Winnipeg, mb / accesswire / november 23, 2023 / medicure inc. ("medicure" or the "company") (tsxv:mph)(otc pink:mcujf), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the united states market, today announced that the fda provides complete approval to enroll patients in its pivotal phase 3 clinical trial to evaluate the use of its investigational product mc-1 for treatment of a rare pediatric disease called pyridox(am)ine 5′-phosphate oxidase (pnpo) deficiency. the study involves approximately 10 patients at sites in the united states and australia, and the company is seeking marketing approval initially in those countries.
Latest News
2024-04-04 18:00:00 - Accesswire
Medicure To Present Financial Results on April 9, 2024 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2023
WINNIPEG, MB / ACCESSWIRE / April 4, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Year End Financial Results on a Conference Call on April 9, 2024 at 8:30 am Eastern Time. The 2023 Year End Financials will be filed after closing April 8, 2024.
2023-07-24 19:00:00 - Accesswire
Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023
WINNIPEG, MB / ACCESSWIRE / July 24, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Q2 Financial Results on a Conference Call on July 31, 2023 at 8:30 am Eastern Time. The Q2 Financials will be filed after closing July 28th, 2023.
2023-04-05 14:00:00 - Accesswire
Medicure To Present Financial Results on April 10, 2023 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2022
WINNIPEG, MB / ACCESSWIRE / April 5, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2022 Year End Financial Results on a Conference Call on April 10, 2023 at 8:30 am Eastern Time. The 2022 Year End Financials will be filed after closing on April 6, 2023 ahead of the Good Friday holiday on April 7, 2023 (markets closed).
2022-11-25 11:02:10 - Seeking Alpha
Medicure Inc. (MCUJF) Q3 2022 Earnings Call Transcript
Medicure Inc. (OTCPK:MCUJF) Q3 2022 Results Conference Call November 25, 2022 8:30 AM ET Company Participants Dr. Albert Friesen - CEO Dr. Neil Owens - President and COO Haaris Uddin - CFO Conference Call Participants Kurt Caramanidis - Carl M. Hennig, Inc. Operator Good morning, ladies and gentlemen and welcome to Medicure's Earnings Conference Call for the Quarter Ended September 30, 2022.
2022-11-17 17:00:00 - PRNewsWire
MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2022
WINNIPEG, MB , Nov. 17, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q3 Financial Results on a Conference Call on November 25, 2022 at 8:30 am Eastern Time. The Q3 Financials will be filed after closing the day before.
2022-08-17 17:00:00 - PRNewsWire
MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022
WINNIPEG, MB , Aug. 17, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q2 Financial Results on a Conference Call on August 25, 2022 at 8:30 am Eastern Time. The Q2 Financials will be filed after closing the day before.
2022-04-26 13:00:00 - PRNewsWire
MEDICURE TO REPORT FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2021 ON APRIL 28TH AT 7:30 AM CST
WINNIPEG, MB , April 26, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announces Medicure's 2021 Year End Results Conference Call. Conference Call Info: Topic: Medicure's 2021 Year End Results Call date: Thursday, April 28, 2022 Time: 7:30 AM Central Time (8:30 AM Eastern Time) Canada toll: 1 (416) 764-8659 North American toll-free: 1 (888) 664-6392 Passcode: not required Webcast: This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: www...
2022-01-20 09:26:45 - Proactive Investors
MedX Health launches DermSecure screening services at Medicure clinic in Mississauga, Ontario
MedX Health Corp revealed that it is now offering its DermSecure screening services at the Medicure (TSX-V:MPH) clinic in Mississauga, Ontario - the first launch of its platform in a blended physician and pharmacy clinic setting in Canada. Under the tie-up, Medx's scanning services are now available to the clinic's 5,000 existing family physician patients as well as walk-in patients through the on-site pharmacy.
2021-08-30 09:50:40 - Seeking Alpha
Medicure Inc. (MCUJF) CEO Albert Friesen on Q2 2021 Results - Earnings Call Transcript
2021-08-27 17:00:00 - PRNewsWire
Medicure Reports Financial Results for the Second Quarter Ended June 30, 2021
WINNIPEG, MB, Aug. 27, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2021. Quarter Ended June 30, 2021 Highlights: Recorded total net revenue from the sale of products of $5.09 million during the second quarter ended June 30, 2021 compared to $2.68 million for the second quarter ended June 30, 2020; Recorded total net revenue from the sale of AGGRASTAT® of $2.8 million during the second quarter ended June 30, 2021 compared to $2.6 million for the second quarter ended June 30, 2020; Net loss for the second quarter ended June 30, 2021 was $639,000 compared to net income of $19,000 for the second quarter ended June 30, 2020; Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA1) for the second quarter ended June 30, 2021 was $158,000 compared to adjusted EBITDA of $263,000 for the second quarter ended June 30, 2020 Financial Results Net revenues for the three months ended June 30, 2021 were $5...